Huntington disease (HD) has finally found its first successful treatment. Biotech company uniQure has announced positive top-line results from its Phase I/II trial of AMT-130. It is a one-time gene ...
Qure N.V. hinges on the AMT-130 FDA outcome; a Type B meeting may help, but Phase 3 is likely. Click for this updated look at ...
LEXINGTON, Mass. and AMSTERDAM, Nov. 03, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, ...
uniQure announces FDA's Breakthrough Therapy designation for AMT-130, with promising Phase I/II trial safety data and upcoming regulatory updates. uniQure N.V. has announced that its gene therapy ...
uniQure recently divested from its Lexington facility to Genezen and freed $25 million while significantly reducing its operating costs. At the same time, AMT-130 has received the FDA’s Breakthrough ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results